Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07900542). This is a study registration, not published results. Lead sponsor: Hamad Medical Corporation. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 1000 participants (ESTIMATED). Conditions: Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection. Interventions: OTHER: No Intervention: Observational Cohort. Primary outcome measures: Overall BSI incidence per 1,000 patient days , 30 days. Brief summary: The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies and stem cell transplant recipients across the Middle East. The objectives are to describe the epidemiological trends, identify risk factors for inappropriate antimicrobial therapy, and predictors of persistent BSI, microbiological relapse, and all-cause mortality. The study is entirely observational, participants will receive standard clinical care as directed by their treating doctors.